NCT07493629Recruiting
Immune Status and Disease Control of Inflammatory Airway Diseases
Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled. Participants will: 1. Answer questions about their health and symptoms. 2. Give blood samples 3. Have lung function tests and other standard check-ups. 4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 24 Aug 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- First Affiliated Hospital of Ningbo University
- NCT number
- NCT07493629
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Aug 2025 to the primary completion date, 1 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)
Other illness
- Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.
- Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.
Other
- Pregnant or lactating women.
- Patients with poor compliance as judged by the investigators.
- Subjects currently participating in other clinical studies.
Who the study is looking for
- Age ≥18 years (≥40 years for COPD patients).
- Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.
- PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 \<80% predicted)
- Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.
- Healthy controls: normal lung function, FeNO \<20 ppb, total IgE \<100 IU/mL, no chronic disease, smoking \<10 pack-years, no immunosuppressant use within 3 months.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Ningbo University Coordinator of this site? Confirm its status | Ningbo | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.